Activation of innate anti-viral immune response genes in symptomatic benign prostatic hyperplasia

Genes and Immunity

Volumn 13, Issue 7, 2012, Pages 566-572

  Madigan, A A ^a   Sobek, K M ^a   Cummings, J L ^a   Green, W R ^a   Bacich, D J ^a   Okeefe, D S ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

anti viral immune response; APOBEC3G; benign prostatic hyperplasia; BPH; CFI; LINE 1

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; COMPLEMENT FACTOR I; GENOMIC DNA; SYNTHETASE; TETRATRICOPEPTIDE REPEAT PROTEIN;

ARTICLE; DNA METHYLATION; GENE EXPRESSION REGULATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE GENE; INNATE IMMUNITY; LONG INTERSPERSED REPEAT; MALE; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; RETROPOSON; TRANSURETHRAL RESECTION; UPREGULATION; VIRUS IMMUNITY;

CARRIER PROTEINS; COMPLEMENT FACTOR I; CYTIDINE DEAMINASE; DNA METHYLATION; HUMANS; IMMUNITY, INNATE; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; MALE; PROSTATIC HYPERPLASIA; RNA, MESSENGER; UP-REGULATION;

EID: 84867745963     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2012.40     Document Type: Article

References (26)

1. Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol 2005; 173: 1309-1313.
2. Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A, Ruud Bosch JL. Normal voiding patterns and determinants of increased diurnal and nocturnal voiding frequency in elderly men. J Urol 2000; 164: 1201-1205.
3. Ventura S, Oliver V, White CW, Xie JH, Haynes JM, Exintaris B. Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). Br J Pharmacol 2011; 163: 891-907.
4. Ropiquet F, Giri D, Lamb DJ, FGF7 Ittmann M. and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. J Urol 1999; 162: 595-599.
5. Dong G, Rajah R, Vu T, Hoffman AR, Rosenfeld RG, Roberts CT et al. Decreased expression of Wilms' tumor gene WT-1 and elevated expression of insulin growth factor-II (IGF-II) and type 1 IGF receptor genes in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 1997; 82: 2198-2203.
6. Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyper-plasia: past, present and future. Differentiation 2011; 82: 184-199.
7. Schauer IG, Rowley DR. The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation 2011; 82: 200-210.
8. Zhao H, Ramos CF, Brooks JD, Peehl DM. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. J Cell Physiol 2007; 210: 111-121.
9. Janeway C, Travers P, Walport M, Shlomchik M. Immunobiology, The Immune System in Health and Disease. 5th edn Garland Science: New York, 2001.
10. Santourlidis S, Florl A, Ackermann R, Wirtz HC, Schulz WA. High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate 1999; 39: 166-174.
11. Bhutani N, Burns DM, Blau HM. DNA demethylation dynamics. Cell 2011; 146: 866-872.
12. Chiu YL, Greene WC. APOBEC3G: an intracellular centurion. Philos Trans R Soc Lond B Biol Sci 2009; 364: 689-703.
13. Fensterl V, Sen GC. The ISG56/IFIT1 gene family. J Interferon Cytokine Res 2011; 31: 71-78.
14. Sahu A, Isaacs SN, Soulika AM, Lambris JD. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. J Immunol 1998; 160: 5596-5604.
15. Johnson JB, Grant K, Parks GD. The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 to evade complement-mediated neutralization. J Virol 2009; 83: 7602-7611.
16. Mold C, Bradt BM, Nemerow GR, Cooper NR. Epstein-Barr virus regulates activation and processing of the third component of complement. J Exp Med 1988; 168: 949-969.
17. Okroj M, Hsu YF, Ajona D, Pio R, Blom AM. Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol 2008; 45: 169-179.
18. Gasque P, Julen N, Ischenko AM, Picot C, Mauger C, Chauzy C et al. Expression of complement components of the alternative pathway by glioma cell lines. J Immunol 1992; 149: 1381-1387.
19. Minta JO, Fung M, Paramaswara B. Transcriptional and post-transcriptional regulation of complement factor I (CFI) gene expression in Hep G2 cells by inter-leukin-6. Biochim Biophys Acta 1998; 1442: 286-295.
20. Timár KK, Junnikkala S, Dallos A, Jarva H, Bhuiyan ZA, Meri S et al. Human kera-tinocytes produce the complement inhibitor factor I: Synthesis is regulated by interferon-gamma. Mol Immunol 2007; 44: 2943-2949.
21. Pichlmair A, Lassnig C, Eberle CA, Górna MW, Baumann CL, Burkard TR et al. IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nat Immunol 2011; 12: 624-630.
22. Sutcliffe S, Rohrmann S, Giovannucci E, Nelson KE, De Marzo AM, Isaacs WB et al. Viral infections and lower urinary tract symptoms in the third national health and nutrition examination survey. J Urol 2007; 178: 2181-2185.
23. Breyer BN, Van den Eeden SK, Horberg MA, Eisenberg ML, Deng DY, Smith JF et al. HIV status is an independent risk factor for reporting lower urinary tract symptoms. J Urol 2011; 185: 1710-1715.
24. Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjogren's syndrome. J Autoimmun 2010; 35: 225-231.
25. Zisman A, Zisman E, Lindner A, Velikanov S, Siegel YI, Mozes E. Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia. J Urol 1995; 154: 1052-1055.
26. Yang AS, Estécio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004; 32: e38.